The name commemorated with the birth of pharma industry in Gujarat is none other than that of Alembic Ltd., the first firm to set up its facility and roll out pharma business in the jewel of the West. The company, which started operations in the state in 1907, is now Asia's most respected integrated pharmaceutical company with networks in 75 countries globally. The company, which has manufacturing facilities in Baroda and Baddi, spearheads landmark research in the areas of chemistry, microbiology, pharmaceutical technology and bio equivalence.
During its growth over the years, Alembic has succeeded in grabbing ISO-9002, ISO-14001 and ISO 27001certification and built up manufacturing practices and facilities that conform to WHO-GMP guidelines. Now the company is also spreading its wings to regulatory markets both in respect of active pharmaceutical ingredient (API) and formulation.
The company, which has made its mark in API, bulk pharma chemicals, formulations, herbals, nutraceuticals and contract/collaborated research services, recognises research and development vital for its survival and growth. Alembic's net work spans 75 countries globally.
Chirayu R Amin is the company's chairman and managing director. In an interview with Gireesh Babu, Chirayu R Amin deliberated at length on the compay's CRAMS business and growth strategies. Excerpts:
Several of the Indian Pharma companies are turning into CRAMS business as a perspective growth engine in the near future. How does Alembic looks at CRAMS as an opportunity?
Alembic has significant strengths in R&D and manufacturing, both for API's as well as formulations. We are already doing contract manufacturing for a leading MNC in probably one of the larger outsourcing deals in India. To achieve our target of Rs 2000 crore by FY2010, contract manufacturing for MNCs will be an important area.
Which are the key focus areas Alembic look at in the contract manufacturing (outsourcing) industry?
We look at the market opportunity for products, analyse our strengths in making the products and consider what value-additions we can bring to the product to ultimately help the patient.
Alembic has now completed 100 years of its operation in Gujarat. At this juncture, do you think the business culture of Gujarat is a great facilitator? Why?
The culture of Gujarat has always promoted entrepreneurship and I strongly feel it should continue. The regulatory environment, the infrastructure, etc are conducive to the growth of pharma industry. The government realises that pharma is an important industry and is providing necessary facilities to develop Gujarat as a pharma hub. The setting up of SEZs will further boost the capabilities for the pharma industry.
Alembic is reportedly pursuing the inorganic route to spread its global reach. Could you brief us on your latest plans and strategies in this direction?
We are continuously looking for opportunities. Any acquisition should make business sense for us and not just be done for the sake of growth. We wish to grow, and grow profitably.